Speaker: Subhankar Mandal
Topic: Overview of SARS Corona Virus and Vaccine Development
Date & Time: Thursday, 9 September 2021 at 4:00 PM through MICROSOFT TEAMS
The world is amidthe COVID-19 pandemic and the entire vaccinology scientific community has been busy developing numerous types of safe and effective vaccines against the SARS CoV-2. The SARS-CoV-2 virus isan RNA virus that belongs to the coronaviridae family and causes COVID-19 disease. It makes use of a densely glycosylated spike(S) protein to enter host cells. The S-protein is a trimeric class-I fusion protein existing in a metastable prefusion conformation and undergoes a substantial structural rearrangement to fuse the viral membrane with that of the host cell membrane. This S protein attaches with the human-ACE2 receptor to enter our body with a second critical fusion machinery mechanism.
In the seminar, I will first introduce the origin of vaccines anda basic ideaof immune system response when any virus or bacteria enter in our body. Then, I willtalk about the structural information of spike proteins of SARS CoV-1 versus SARS CoV-2 followed by the insertion mechanism. I will conclude my discussion with kinetics of the fusion process of VSV G proteinand vaccine development strategy.
(1) Bavari et al. “Broad-Spectrum Coronavirus Antiviral Drug Discovery.” Expert Opin. Drug Discov.2019, 14 (4), 397–412.doi:org/10.1080/17460441.2019.1581171.
(2) Barcena et al. “Cryo-Electron Tomography of Mouse Hepatitis Virus : Insights into the Structure of the Coronavirion.” Proc. Natl. Acad. Sci. U. S. A.2009, 106, 582-587. doi: 10.1073pnas.0805270106.
(3) Wrapp et al.“Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformati -on.” Science2020, 367 (6483), 1260–1263. doi:org/10.1126/science.aax0902.
(4) Kim et al. “Mechanism of Membrane Fusion Induced by Vesicular Stomatitis Virus G Protein.”Proc. Natl. Acad. Sci. U. S. A.2016, 114, E28-E36. doi:org/10.1073/pnas.1618883114.
(5) Kyriakidis, N. C. et al.“SARS-CoV-2 Vaccines Strategies : A Comprehensive Review of Phase 3 Candidates.” npj Vaccines2021.28,17.doi: org/10.1038/s41541-021-00292-w.